Compare American Express Co (AXP) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Express Co vs Quest Diagnostics Inc — how do they compare? American Express Co trades at $360.88 (market cap $242.27B), while Quest Diagnostics Inc trades at $206.04 (market cap $22.80B). The key difference: American Express Co is far larger — about 10.6× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays the higher dividend (1.67%). Which is the better fit depends on your goals.
| AXP | DGX | |
|---|---|---|
Market Cap | $242.27B | $22.80B |
Sector | Financials | Health |
52-Week High | $384.82 | $216.02 |
52-Week Low | $292.27 | $166.42 |
Dividend Yield | 1.07% | 1.67% |
Enterprise Value | — | $28.82B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AXP trades at $354.43, up 1.1% today, with a bullish technical signal from moving averages and support at $352. The company reported strong Q1 2026 earnings of $4.28 per share, beating estimates, with revenue reaching $72.23 billion in 2025. Recent news highlights AI investments and a new headquarters, while analyst consensus is a $373.62 price target with 40% buy ratings.
Outlook remains positive driven by revenue growth and premium cardholder expansion, but risks include economic sensitivity and rising debt levels. The stock offers potential upside to consensus targets, supported by institutional confidence and operational momentum, though investors should monitor spending trends and interest rate impacts.
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Express Co
American Express Company is a global payment and travel company. The Company's principal products and services are charge and credit payment card products and travel-related services offered to consumers and businesses around the world.
Read more on AXP →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
